BioCentury
ARTICLE | Financial News

Provention plans IPO, reveals MacroGenics deal

May 10, 2018 8:14 PM UTC

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed from other companies and which are designed to intercept and prevent diseases (see BioCentury, Sept. 29, 2017).

In a separate announcement Wednesday, Provention announced a pair of deals with MacroGenics Inc. (NASDAQ:MGRX) in which Provention acquired Type I diabetes treatment teplizumab (PRV-031) and obtained exclusive, worldwide rights to systemic lupus erythematosus (SLE) candidate PRV-3279 (formerly MGD010). ...